DAVID D. CHISM, MD, MS

Curriculum Vitae | Medical Oncologist/Hematologist

Knoxville, Tennessee | david.chism@gmail.com | 629-262-8278

Professional Profile

Board-certified medical oncologist/hematologist, clinical investigator, educator, and physician leader with more than a decade of oncology practice spanning academic and community settings in Tennessee and North Carolina. Former Assistant Professor at Vanderbilt-Ingram Cancer Center and former Medical Director of Clinical Research in Knoxville, with experience delivering comprehensive cancer care, leading multidisciplinary genitourinary oncology, and overseeing investigator-initiated and industry-sponsored clinical trials. National leadership through ASCO and ABIM complements extensive experience in regional cancer care. Brings established East Tennessee clinical experience, expertise in solid tumors and hematology/oncology, and a strong interest in connecting community-based practice with academic tumor boards, clinical trials, subspecialty collaboration, and innovative therapeutics.

Clinical and Professional Focus

- Comprehensive medical oncology and hematology care in academic and community settings
- Genitourinary oncology: prostate, bladder/urothelial, kidney, and testicular cancers
- Multidisciplinary cancer care, tumor boards, clinical trials, and access to novel therapeutics
- Regional and community oncology, including delivery of high-quality cancer care close to home across East Tennessee
- Physician leadership, quality, patient safety, research oversight, medical education, and mentorship

Education and Postgraduate Training

Physician Executive MBA (PEMBA), Candidate — Haslam College of Business, University of Tennessee, Knoxville, TN
2027–2028 (anticipated)

Hematology-Oncology Fellowship — University of North Carolina, Chapel Hill, NC
2011–2014

Internal Medicine Residency — UMDNJ–Robert Wood Johnson, New Brunswick, NJ
2008–2011

M.D. — University of Tennessee College of Medicine, Memphis, TN
2004–2008

M.S., Cell and Molecular Biology — Tulane University, New Orleans, LA
2002–2003

Post-baccalaureate, Pre-Medicine — Harvard University Extension School, Cambridge, MA
1998–2001

NIH/NIDA Predoctoral Fellow — National Institutes of Health, Washington, DC
1997–1998

B.A., Psychology — Georgetown University, Washington, DC
1993–1997

Academic and Professional Appointments

Hematology/Oncology Physician — Tennessee Oncology, LLC, Alcoa/Knoxville, TN
May 2025–Present

- Community hematology/oncology practice serving Alcoa/Knoxville and East Tennessee, with care across solid tumors and hematologic conditions and a major clinical focus in genitourinary malignancies; integrates contemporary systemic therapies and multidisciplinary referral pathways into regional cancer care.

Medical Director of Clinical Research — Thompson Cancer Survival Center, Knoxville, TN
January 2020–December 2024

- Provided medical direction, strategy, and operational oversight for the oncology clinical research program.
- Led multidisciplinary teams in the design, implementation, and evaluation of clinical trials and correlative science studies.

- Oversaw research quality, patient safety, regulatory compliance, and ethical conduct.

Hematology/Oncology Physician — Thompson Cancer Survival Center, Knoxville, TN
January 2019–December 2024
Assistant Professor of Medicine, Hematology/Oncology — Vanderbilt University Medical Center / Vanderbilt-Ingram Cancer Center, Nashville, TN
January 2016–January 2019

- Focused clinical and scholarly practice in genitourinary oncology.
- Led the genitourinary multidisciplinary clinic, coordinating medical oncology, urologic oncology, radiation oncology, pathology, radiology, and supportive care.
- Participated in clinical trials, institutional scientific review, and trainee education.

Medical Oncologist — Wesley Long Cancer Center, Greensboro, NC
May 2014–December 2015
Hospitalist (part-time during fellowship) — University of North Carolina, Chapel Hill, NC
January 2012–June 2014

National Leadership, Academic Service, and Committees

Member, ABIM Medical Oncology Item-Writing Committee, 2024–Present.

Member, Tennessee Oncology Health Equity and Community Engagement Steering Committee

Past Chair / Inaugural Chair, ASCO Health Services Research Committee (Chair May 2025–May 2026); work focused on cancer-care delivery, workforce sustainability, quality, access, and high-value oncology care.

Member, ASCO Cancer Care Impact Committee, 2022–2026.

Graduate, ASCO Leadership Development Program, Class of 2023.

Former NCCN Testicular Cancer Panel Member, 2017–2019.

Former member, Vanderbilt-Ingram Cancer Center Scientific Review Committee and Institutional Biosafety Committee–Human Subjects, 2017–2019.

Former member, Renal Cell Clinical Trial Consortium, 2017–2019.

University of Tennessee Knoxville Chancellor's Associate, 2021–2024

Member, ASCO Professional Development Committee, 2016–2018.

Teaching and Mentorship

- Teaching and mentorship of medical students, residents, fellows, advanced practice clinicians, and oncology staff across academic and community settings.
- Multidisciplinary case-based education in genitourinary oncology, including prostate, bladder, kidney, and testicular malignancies.
- Ongoing national educational participation through oncology panels, advisory programs, professional committees, and invited presentations.

Selected Presentations

- Chism DD. Inaugural Faculty Speaker, "Theranostics: Foundation to Frontline." Appalachian Radiotheranostics Coalition, Theranostics Program; University of Tennessee Medical Center, Wood Auditorium; Knoxville, TN; April 18, 2026.
- Chism DD, Kirkwood MK, Perla S, Accordino MK, et al. Research training and career intentions among medical oncology fellows amid US federal funding shifts: A national cross-sectional study. ASCO Quality Care Symposium; Boston, MA; October 2026.
- Chism DD. The Future of Clinical Research. Cancer Support Network of Knoxville; Knoxville, TN; December 2025.

Research and Scholarly Focus

- Genitourinary cancer biology and therapeutics, including molecular subtypes of bladder cancer, androgen-receptor resistance in prostate cancer, renal-cell carcinoma biomarkers, and immunotherapy.

- Cancer-care delivery and health services research, including access to clinical trials, oncology workforce sustainability, disparities, and implementation of high-value care.
- Community-academic clinical research infrastructure and expansion of access to complex and novel therapies for patients in East Tennessee and rural communities.

Selected Honors and Awards

- Certificate of Recognition, Inaugural Faculty Speaker, Appalachian Radiotheranostics Coalition, 2026
- Castle Connolly Top Doctors, Medical Oncology, 2021–2026
- Best in Tennessee Magazine Doctors – Excellence in Oncology, 2025–2026
- ASCO Ambassador
- Vanderbilt-Ingram Cancer Center Star Award, 2017
- John William Pope Clinical Fellow Clinical/Translational Cancer Research Award, 2014
- ASCO Merit Award, 2014

Board Certification and Licensure

- American Board of Internal Medicine — Internal Medicine (active)
- American Board of Internal Medicine — Medical Oncology (active)
- Tennessee medical license (active; expiration November 2028)
- ACLS certification (active; expiration December 2026)

Professional Memberships

- American Society of Clinical Oncology (ASCO), 2014–Present
- NRG Oncology, 2015–Present

Peer Review and Editorial Service

- Bladder Cancer — former Ad Hoc Reviewer
- Urology — former Ad Hoc Reviewer
- Urologic Oncology: Seminars and Original Investigations — former Ad Hoc Reviewer
- Oncotarget — former Ad Hoc Reviewer
- Journal of Clinical Investigation —former Ad Hoc Reviewer

Selected Publications

1. Balogh EP, Levit LA, Unger JM, et al. ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States. JCO Oncology Practice. 2025;21:1746-1758.

2. Kirkwood MK, Balogh EP, Accordino MK, et al. Where have we been and where are we going? The state of hematology and medical oncology workforce in America. JCO Oncology Practice. 2025;21:1775-1785.

3. Bidard F-C, Mayer IA, Park YH, et al. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025;393(6):569-580.

4. Petrylak DP, Eigl BJ, George S, et al. Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. Clin Cancer Res. 2024;30(1):63-73.

5. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907-1918.

6. Gilligan T, Lin DW, Aggarwal R, et al. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:1529-1554.

7. Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, et al. Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement from the American Heart Association. Circulation. 2019;139:e579-e602.

8. Choueiri TK, Larkin J, Oya M, et al. Preliminary results for avelumab plus axitinib as first-line therapy in advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100). Lancet Oncol. 2018;19:451-460.

9. Rose TL, Chism DD, Alva AS, et al. Phase II trial of palbociclib in metastatic urothelial cancer after failure of first-line chemotherapy. Br J Cancer. 2018;119:801-807.

10. Chism DD. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy. J Natl Compr Canc Netw. 2017;15:1277-1284.

11. Chism DD, De Silva D, Whang YE. Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2014;14:1369-1378.

12. Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111:3110-3115.

Additional Publications and Abstracts

40+ peer-reviewed publications, reviews, book chapters, and meeting abstracts spanning genitourinary oncology, cancer biology, immunotherapy, COVID-19 and cancer, cardio-oncology, and health services research. A complete publication list can be provided with the application or retained as an appendix.

Book Chapters

1. Chism DD, Apolo A, Milowsky M. Chemotherapy for Metastatic Bladder Cancer. In: Xylinas E, Shariat SF, eds. Advances in Bladder Cancer Management. Future Science; 2015.

2. Chism DD, Rathmell WK. Prognostic and Predictive Biomarkers in Renal Cell Carcinoma. In: Tannir N, ed. Renal Cell Carcinoma. Oxford American Oncology Library. Oxford University Press; 2014.

Consulting / Scientific Advisory Activities

- AstraZeneca — Breast Cancer National Advisory Board, 2023
- Regeneron — Lung Cancer National Advisory Board, 2023
- Pfizer — Kidney Cancer National Advisory Board, 2018
- Karyopharm — Prostate Cancer National Advisory Board, 2017
- Exelixis — Kidney Cancer National Advisory Board, 2016